863704-60-3

Basic information

• Product Name: 6-(4-Fluorophenyl)-picolinic acid
• Synonyms: 6-(4-Fluorophenyl)-picolinic acid;6-(4-Fluorophenyl)
• CAS NO: 863704-60-3
• Molecular Formula: C₁₂H₈FNO₂
• Molecular Weight: 217.2
• Mol File: 863704-60-3.mol

Chemical Properties

• Boiling Point: 404.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.318±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.67±0.25(Predicted)
• CAS DataBase Reference: 6-(4-Fluorophenyl)-picolinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(4-Fluorophenyl)-picolinic acid(863704-60-3)
• EPA Substance Registry System: 6-(4-Fluorophenyl)-picolinic acid(863704-60-3)

Safety Data

• Hazardous Substances Data: 863704-60-3(Hazardous Substances Data)

Usage

Uses

6-(4-Fluorophenyl)picolinic acid

Upstream product

• 225916-39-2 2-(4-fluorophenyl)-5,5-dimethyl-1,3,2-dioxaborinane 
• 21190-87-4 6-bromo-pyridine-2-carboxylic acid 
• 1765-93-1 4-fluoroboronic acid 
• 26218-75-7 methyl 6-Bromopicolinate 
• 1390624-20-0 6-(4-fluorophenyl)pyridine-2-carboxylic acid methyl ester 
• 122918-25-6 6-bromopyridin-2-carbonitrile 

Downstream Products

• 868734-73-0 6-(4-fluorophenyl)picolinic acid N-oxide 
• 1390624-23-3 5-chloro-3-[6-(4-fluorophenyl)pyridin-2-yl]-6-methyl-7,8-dihydro-6H-9-oxa-1,2,3a,4,6-pentaaza-cyclopenta[a]naphthalene 

Relevant articles and documents

Structure-Activity Relationship for the Picolinamide Antibacterials that Selectively Target Clostridioides difficile

Clostridioides difficile is a leading health threat. This pathogen initiates intestinal infections during gut microbiota dysbiosis caused by oral administration of antibiotics. C. difficile is difficult to eradicate due to its ability to form spores, which are not susceptible to antibiotics. To address the urgent need for treating recurrent C. difficile infection, antibiotics that selectively target C. difficile over common gut microbiota are needed. We herein describe the class of picolinamide antibacterials which show potent and selective activity against C. difficile. The structure-activity relationship of 108 analogues of isonicotinamide 4, a compound that is equally active against methicillin-resistant Staphylococcus aureus and C. difficile, was investigated. Introduction of the picolinamide core as exemplified by analogue 87 resulted in exquisite potency and selectivity against C. difficile. The ability of the picolinamide class to selectively target C. difficile and to prevent gut dysbiosis holds promise for the treatment of recurrent C. difficile infection.

Picolinamide compound and preparation method and application thereof

The invention discloses a picolinamide compound. The structural general formulas of the picolinamide compound are shown as formulas (I) and (II). The invention also discloses a preparation method of the picolinamide compound and application of the picolinamide compound in preparation of anti-tumor drugs. The picolinamide compound can effectively inhibit a variety of tumor cells, including human breast cancer cells, human lung cancer cells, human liver cancer cells and the like, has good anti-tumor active substances and can be used for preparing the anti-tumor drugs.

6, 7-RING-FUSED TRIAZOLO [4, 3 - B] PYRIDAZINE DERIVATIVES AS PIM INHIBITORS

There is provided compounds of formula I, wherein R1, R2, R3 and R4 (and the -CH2-CH2 moiety) have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvate

Discovery of pyrrolopyridine-pyridone based inhibitors of met kinase: Synthesis, X-ray crystallographic analysis, and biological activities

Conformationally constrained 2-pyridone analogue 2 is a potent Met kinase inhibitor with an IC50 value of 1.8 nM. Further SAR of the 2-pyridone based inhibitors of Met kinase led to potent 4-pyridone and pyridine N-oxide inhibitors such as 3 and 4. The X-ray crystallographic data of the inhibitor 2 bound to the ATP binding site of Met kinase protein provided insight into the binding modes of these inhibitors, and the SAR of this series of analogues was rationalized. Many of these analogues showed potent antiproliferative activities against the Met dependent GTL-16 gastric carcinoma cell line. Compound 2 also inhibited Flt-3 and VEGFR-2 kinases with IC50 values of 4 and 27 nM, respectively. It possesses a favorable pharmacokinetic profile in mice and demonstrates significant in vivo antitumor activity in the GTL-16 human gastric carcinoma xenograft model.

Met kinase inhibitors

The present invention is directed to compounds that are useful for treating cancer having one of the following Formulas:

Monocyclic heterocycles as kinase inhibitors

The present invention is directed to compounds having the formula and methods for using them for the treatment of cancer.

EP2 RECEPTOR AGONISTS

A compound of Formula (I) or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of Formulae (Ai), (Aii), (Aiii) D is selected from Formulae (Di), (Dii), (Diii), (Div), (Dv) B is selected from the group consisting of Formulae (Bi), (Bii), (Biii), (Biv) (Bv).